# What Patients Need to Know About the Remission Rate of Glioblastomas

Patients are overwhelmed when they are diagnosed with glioblastoma, the most deadly primary brain cancer. It resists existing treatments and recurs in all patients, with a relatively short survival time averaging 14-18 months. Understanding the rate of remission for this disease can therefore enable patients and their caregivers to have a clear picture of what to expect, and therefore be guided in making any decisions they need to make. We discuss some of the factors influencing remission in GBM.

 Given that only 25% of people diagnosed with GBM experience remission lasting at least two years, the success rates of current treatments indicated for glioblastomas are very low indeed. This is the reason why companies like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) and the…

 Read More>>

 NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP

 About BioMedWire

 BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

 BMW is where breaking news, insightful content and actionable information converge.

 To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

 For more information, please visit https://www.BioMedWire.com

 Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

 BioMedWireSan Francisco, CAwww.BioMedWire.com415.949.5050 OfficeEditor@BioMedWire.com

 BioMedWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/bmw/what-patients-need-to-know-about-the-remission-rate-of-glioblastomas/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/glioblastoma-s-grim-reality-75-don-t-reach-2-year-remission/4029a7d38f5bdc45cf35735ad11b0228) 


Pickup - [https://burstable.news/news](https://burstable.news/news/202510/267576-understanding-glioblastoma-remission-rates-provides-critical-guidance-for-patients-and-families)

Pickup - [https://estallarnoticias.com/](https://estallarnoticias.com//202510/267585-tasa-de-remision-del-glioblastoma-solo-el-25-de-pacientes-logra-remision-de-dos-anos)

Pickup - [https://platzennachrichten.de/nachrichten](https://platzennachrichten.de/nachrichten/202510/267666-glioblastom-remissionsraten-nur-25-der-patienten-erleben-zweijahrige-remission)

Pickup - [https://actueclair.com](https://actueclair.com/202510/267643-taux-de-remission-du-glioblastome-seulement-25-des-patients-atteignent-une-remission-de-deux-ans)
 

 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/2510/28/filob311.webp)